Exosome Sciences, Inc., in collaboration with majority shareholder Aethlon Medical, Inc. (Nasdaq: AEMD), announced, on January 12, 2016, that it has agreed to participate in a clinical research study to establish methods for detecting and diagnosing chronic traumatic encephalopathy (CTE) during life, as well as examining risk factors for CTE. CTE is a disease of the brain often found in athletes, military veterans, and others with a history of repetitive head impacts. At present, CTE can only be definitively diagnosed through post-mortem examination of brain tissue. The research study will be conducted under a $16 million grant that the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) has awarded to researchers from Boston University, the Cleveland Clinic, Banner Alzheimer's Institute, and Brigham and Women's Hospital in Boston. Overall, the project will involve a group of approximately 50 investigators, representing 17 research institutions. Exosome Sciences has agreed to test an exosomal tau biomarker (TauSome™) that it has been advancing as a blood-based candidate to diagnose CTE. "We are truly grateful that our colleagues at the Boston University CTE Center have expanded our opportunity to validate our Tausome™ biomarker as a candidate to detect and monitor CTE in living individuals," stated Jim Joyce, Executive Chairman at Exosome Sciences and Chairman and CEO of Aethlon Medical. Mr. Joyce played college football for the University of Maryland, and later played briefly in the NFL for the now-Super-Bowl-bound Denver Broncos, before turning to business and biotech.
Login Or Register To Read Full Story